Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Endo Health Solutions Inc    ENDP

ENDO HEALTH SOLUTIONS INC (ENDP)
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Endo Pharmaceuticals Swings To 1Q Loss On Litigation Impacts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/01/2012 | 02:13pm CEST

Endo Pharmaceuticals Holdings Inc.'s (>> Endo Pharmaceuticals Holdings Inc) swung to a first-quarter loss, mostly owing to a $110 million charge related to a 2010 litigation settlement, while the pharmaceutical company reported revenue grew with a boost from a recent acquisition.

Endo has seen its revenue rise in recent quarters, aided by acquisitions that expanded its generic-drug business and core painkiller franchise. But the related charges have hurt its bottom line of late.

First-quarter sales were expected to be affected by a temporary shutdown of a Novartis AG (NVS, Z.NOV) plant in Nebraska to address potential packaging errors. The plant manufactures some Endo products such as its Opana ER painkiller. In the latest period, Opana ER sales were down 4.2%. On Tuesday the company said Opana ER and Voltaren Gel now in steady supply.

Endo reported a loss of $87.3 million, or 75 cents a share, compared with a year-earlier profit of $55.8 million, or 46 cents a share. Excluding impacts from a 2010 litigation settlement with Impax Laboratories Inc. (IPXL), adjusted earnings were down at 87 cents from $1. The company in February expected earnings below 90 cents amid a temporary shutdown at the Novartis plant.

Revenue increased 23% to $691 million, with a boost from its American Medical Systems acquisition. Analysts polled by Thomson Reuters most recently projected $702 million.

Gross margin fell to 47.2% from 58.7%.

Sales of Lidoderm, which makes up the biggest chunk of Endo's top line, were up 11%.

Overall branded drug sales were down 3% while generics sales increased 8%.

Shares of Endo, which reaffirmed its 2012 guidance, closed Monday at $35.14 and were inactive premarket. The stock is down roughly 10% in the past year.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; [email protected]

Stocks mentioned in the article : Endo Pharmaceuticals Holdings Inc
Stocks mentioned in the article
ChangeLast1st jan.
ENDO HEALTH SOLUTIONS INC --End-of-day quote.
IMPAX LABORATORIES INC -1.49% 19.9 Delayed Quote.21.32%
NOVARTIS -1.55% 76.08 Delayed Quote.-7.67%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ENDO HEALTH SOLUTIONS INC
03/23Indivior loses another case in battle to protect opioid addiction drug
RE
01/24City Files Opioid Lawsuit -- WSJ
DJ
01/23New York City Sues Companies Over Opioid Abuse
DJ
01/23New York City sues drug companies over opioid epidemic
RE
01/19Delaware sues opioid manufacturers, distributors over epidemic
RE
01/16ENDO INTERNATIONAL PLC : FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LL..
AC
01/16ENDO INTERNATIONAL PLC : Endo International, OPANA ER is in the News, Vasostrict..
AC
01/15ENDO INTERNATIONAL PLC : FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, L..
AC
01/13ENDO INTERNATIONAL PLC : Pomerantz Law Firm Reminds Shareholders with Losses on..
AC
01/10ENDO INTERNATIONAL PLC : Pomerantz Law Firm Reminds Shareholders with Losses on..
AC
More news
Financials ($)
Sales 2018 2 745 M
EBIT 2018 1 132 M
Net income 2018 -45,8 M
Debt 2018 7 452 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 7,31
EV / Sales 2018 3,16x
EV / Sales 2019 3,11x
Capitalization 1 231 M
Chart ENDO HEALTH SOLUTIONS INC
Duration : Period :
Endo Health Solutions Inc Technical Analysis Chart | ENDP | US29264F2056 | 4-Traders
Technical analysis trends ENDO HEALTH SOLUTIONS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 22
Average target price 8,69 $
Spread / Average Target 58%
EPS Revisions
Managers
NameTitle
Paul V. Campanelli President, Chief Executive Officer & Director
Roger H. Kimmel Chairman
Terrance J. Coughlin Chief Operating Officer & Executive Vice President
Blaise Coleman Chief Financial Officer & Executive Vice President
Nancy J. Hutson Independent Director
Sector and Competitors